Source-grounded facts extracted from Arcturus Therapeutics Holdings Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Arcturus Therapeutics Holdings Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm at the 2026-06-05 meeting.
“Proposal No. 3 For Against Abstain Broker Non-Votes Approval of the ratification of the appointment of Deloitte as the Company's independent registered public accounting firm”
Arcturus Therapeutics Holdings Inc. shareholders approved Approval, on a non-binding advisory basis, the resolution approving named executive officer compensation at the 2026-06-05 meeting.
“Proposal No. 2 For Against Abstain Broker Non-Votes Approval, on a non-binding advisory basis, the resolution approving named executive officer compensation”
Arcturus Therapeutics Holdings Inc. shareholders approved Election of eight directors at the 2026-06-05 meeting.
“Proposal No. 1 For Withhold Broker Non-Votes Approval of the election of the following individuals as directors of the Company”
Arcturus Therapeutics Holdings Inc. reported financial results for the quarter ended March 31, 2026.
“today announced its financial results for the quarter ended March 31, 2026, and provided corporate updates.”
Dennis Mulroy was appointed as Chief Financial Officer at Arcturus Therapeutics Holdings Inc..
“Effective May 1, 2026, Dennis Mulroy, 71, was appointed Chief Financial Officer of the Company.”
Moncef Slaoui was appointed as Member of the Board of Directors at Arcturus Therapeutics Holdings Inc..
“On June 19, 2024, Dr. Moncef Slaoui, Ph.D., agreed to serve as a member of the Board of Directors”
Arcturus Therapeutics Holdings Inc. reported the three months ended March 31, 2024 results: revenue $38.0 million.
“For the three months ended March 31, 2024, revenues were $38.0 million compared with $80.3 million for the three months ended March 31, 2023.”
Arcturus Therapeutics Holdings Inc. engaged Deloitte & Touche LLP as its auditor.
“Effective April 5, 2024, the Audit Committee authorized the appointment of Deloitte & Touche LLP (" Deloitte ") as the Company's new independent registered public accounting firm for the fiscal year ending December 31, 2024, and Deloitte was appointed as the Company's independent registered public accounting firm.”
Arcturus Therapeutics Holdings Inc. dismissed Ernst & Young LLP as its auditor.
“the audit committee of the board of directors (the " Audit Committee ") of Arcturus Therapeutics Holdings Inc.'s (the " Company " or " Arcturus ") authorized the dismissal of Ernst & Young LLP (" EY ") as the Company's independent registered public accounting firm, and EY was dismissed as the Company's independent registered public accounting firm as of such date.”
Arcturus Therapeutics Holdings Inc. reported fiscal fourth quarter 2023 results: revenue $25.0, net income $11.7 million, EPS $0.44 per share.
“the changes affected the fiscal fourth quarter only and resulted in a decrease in collaboration revenue from $160.9 million to $157.7 million for the fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter 2023. This $3.2 million adjustment resulted in an updated net loss of $29.7 million, or $1.12 per share, and $11.7 million, or $0.44 per share, for the fiscal year end and fourth quarter end 2023, respectively.”
Arcturus Therapeutics Holdings Inc. reported fiscal year ended December 31, 2023 results: revenue $157.7 million, net income $29.7 million, EPS $1.12 per share.
“the changes affected the fiscal fourth quarter only and resulted in a decrease in collaboration revenue from $160.9 million to $157.7 million for the fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter 2023. This $3.2 million adjustment resulted in an updated net loss of $29.7 million, or $1.12 per share, and $11.7 million, or $0.44 per share, for the fiscal year end and fourth quarter end 2023, respectively.”
Arcturus Therapeutics Holdings Inc. reported the year ended December 31, 2023 results: revenue $169.9 million.
“For the year ended December 31, 2023, we reported revenue of $169.9 million compared with $206.0 million for the year ended December 31, 2022.”
Arcturus Therapeutics Holdings Inc. reported the three months ended December 31, 2023 results: revenue $34.0 million.
“For the three months ended December 31, 2023, revenue recognized was $34.0 million compared with $160.3 million for the three months ended December 31, 2022.”
Joseph Roberts changed role as Controller at Arcturus Therapeutics Holdings Inc..
“Joseph Roberts, formerly the Company’s Assistant Controller, has been promoted to Controller of the Company.”
Keith C. Kummerfeld resigned as Senior Vice President of Finance and Corporate Controller at Arcturus Therapeutics Holdings Inc..
“Keith C. Kummerfeld, Senior Vice President of Finance and Corporate Controller of Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”), informed the Company that he will resign from his position with the Company, effective March 15, 2024, to pursue another opportunity.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.